InvestSMART

Nyrada Inc (ASX: NYR) - Announcements

Current share price for NYR : $0.460 0.03 (6.12%)+

ASX company news and announcements for Nyrada Inc (NYR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Nyrada Inc (NYR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Nyrada Inc (NYR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Nyrada Inc (NYR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$119 Notification regarding unquoted securities - NYR 15 May 2025 10:37AM $0.105 $0.460 risen by 338.10%
$119 Cleansing Statement 15 May 2025 10:35AM $0.105 $0.460 risen by 338.10%
$119 Application for quotation of securities - NYR 15 May 2025 10:32AM $0.105 $0.460 risen by 338.10%
$119 NYR-BI03 Extends Cardioprotection to Arrhythmia Control 8 May 2025 8:56AM $0.110 $0.460 risen by 318.18%
$119 Phase I Clinical Trial Dosing Update No 2 2 May 2025 8:48AM $0.105 $0.460 risen by 338.10%
$119 Results of Meeting 17 Apr 2025 10:42AM $0.115 $0.460 risen by 300%
$119 Quarterly Activities Report and Appendix 4C 15 Apr 2025 8:23AM $0.115 $0.460 risen by 300%
$119 Notice of Initial Substantial Holder - M Azzi 9 Apr 2025 4:17PM $0.105 $0.460 risen by 338.10%
$119 Phase I Clinical Trial Dosing Update No 1 9 Apr 2025 8:22AM $0.100 $0.460 risen by 360%
$119 Significant Neuroprotection in Traumatic Brain Injury Study 7 Apr 2025 8:27AM $0.094 $0.460 risen by 391.98%
$119 First Cohort Dosed in Nyradas Phase I Clinical Trial 31 Mar 2025 9:52AM $0.110 $0.460 risen by 318.18%
$119 Nyrada Commences Phase I Clinical Trial Recruitment 17 Mar 2025 9:19AM $0.100 $0.460 risen by 360%
$119 2025 EGM Letter to Shareholders, Notice of Meeting and Proxy 12 Mar 2025 8:25AM $0.105 $0.460 risen by 338.10%
$119 Nyrada Half Year Results FY2025 18 Feb 2025 2:15PM $0.082 $0.460 risen by 460.98%
$119 Appendix 4D and Half Year Report to 31 December 2024 18 Feb 2025 2:11PM $0.082 $0.460 risen by 460.98%
$119 Nyrada to Commence Phase Ia Clinical Trial 7 Feb 2025 11:49AM $0.078 $0.460 risen by 489.74%
$119 Quarterly Activities Report and Appendix 4C 23 Jan 2025 11:23AM $0.080 $0.460 risen by 475%
$119 Change of Director's Interest Notice - JM 23 Jan 2025 8:20AM $0.081 $0.460 risen by 467.90%
$119 Change of Director's Interest Notice - MF 22 Jan 2025 8:29AM $0.086 $0.460 risen by 434.88%
$119 Change of Director's Interest Notice - RW 22 Jan 2025 8:29AM $0.086 $0.460 risen by 434.88%
$119 Change of Director's Interest Notice - CC 22 Jan 2025 8:29AM $0.086 $0.460 risen by 434.88%
$119 Change of Director's Interest Notice - ID 21 Jan 2025 5:15PM $0.086 $0.460 risen by 434.88%
$119 Notification of cessation of securities - NYR 21 Jan 2025 4:56PM $0.086 $0.460 risen by 434.88%
$119 NYR-BI03 Phase Ia Clinical Trial Update 2 31 Dec 2024 8:46AM $0.092 $0.460 risen by 400%
$119 Nyrada Receives A$1.235M R&D Tax Incentive Rebate 24 Dec 2024 8:25AM $0.092 $0.460 risen by 400%

201 - 225 of 524 results

Page 9 of 21

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.